409 papers found
Refreshing results…
Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer.
miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis
Genomic Predictors of Outcome in Prostate Cancer
Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution
Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial
Bone scan index as a biomarker to predict outcome in real-life mCRPC patients on abiraterone acetate: A multicenter study.
Quantitative imaging by automated bone scan index (BSI) as a response biomarker in standard clinical care of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.
Synthesis of Biotinylated Galiellalactone Analogues
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
Re: Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer (ARADES): An Open-label Phase 1 Dose-escalation and Randomised Phase 2 Dose Expansion Trial.
Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer.
Degree of Preservation of the Neurovascular Bundles During Radical Prostatectomy and Urinary Continence 1 Year after Surgery
Identification of plasma protein profiles associated with risk groups of prostate cancer patients
Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6
Short-term Results after Robot-assisted Laparoscopic Radical Prostatectomy Compared to Open Radical Prostatectomy
Thromboembolic Complications in 3,544 Patients Undergoing Radical Prostatectomy with or without Lymph Node Dissection
TCF7L2type 2 diabetes risk variant, lifestyle factors, and incidence of prostate cancer: TCF7L2Variant and Prostate Cancer Risk
Targeting STAT3 in castration-resistant prostate cancer: Galiellalactone as a direct inhibitor of STAT3 in prostate cancer cells.
Preclinical characterization of GPA512: A prodrug of a direct STAT3 inhibitor for the treatment of prostate cancer.
Missing publications? Read more about our data sources.